Hepatocellular carcinoma: Systemic treatments

Massimo Di Maio, Ermelinda De Maio, Francesco Perrone, Sandro Pignata, Bruno Daniele

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, with increasing incidence in Western countries. Many pharmacologic treatments have been tested against HCC; most of them belong to three categories: chemotherapy, hormone therapy, and immunotherapy. Neither single agent nor combination chemotherapy have demonstrated a clear reproducible advantage in terms of overall survival; therefore, systemic or intraarterial chemotherapy, should not be considered as standard strategies for patients with HCC. Tamoxifen and antiandrogen therapy were not effective in prolonging survival when tested in randomized, controlled trials. Promising results have been obtained with octreotide in a small randomized trial, but confirmation studies are needed. Although adoptive immunotherapy was effective in the adjuvant setting, interferon should be further investigated in this setting or investigated as a preventive strategy in cirrhotic patients. On the contrary, interferon does not seem to have a role in advanced disease, where it is tolerated poorly. In the future, innovative and promising therapeutic strategies will be tested in HCC, including new biologic target-based drugs, cyclooxygenase inhibitors, and gene therapy.

Original languageEnglish
JournalJournal of Clinical Gastroenterology
Volume35
Issue number5 SUPPL.
DOIs
Publication statusPublished - Nov 2002

Fingerprint

Hepatocellular Carcinoma
Interferons
Adoptive Immunotherapy
Drug Therapy
Androgen Antagonists
Octreotide
Survival
Cyclooxygenase Inhibitors
Tamoxifen
Therapeutics
Combination Drug Therapy
Genetic Therapy
Immunotherapy
Randomized Controlled Trials
Hormones
Incidence
Pharmaceutical Preparations
Neoplasms

Keywords

  • Chemotherapy
  • Hepatocellular carcinoma
  • Hormonal therapy
  • Interferon
  • Pharmacologic treatment

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Hepatocellular carcinoma : Systemic treatments. / Di Maio, Massimo; De Maio, Ermelinda; Perrone, Francesco; Pignata, Sandro; Daniele, Bruno.

In: Journal of Clinical Gastroenterology, Vol. 35, No. 5 SUPPL., 11.2002.

Research output: Contribution to journalArticle

Di Maio, Massimo ; De Maio, Ermelinda ; Perrone, Francesco ; Pignata, Sandro ; Daniele, Bruno. / Hepatocellular carcinoma : Systemic treatments. In: Journal of Clinical Gastroenterology. 2002 ; Vol. 35, No. 5 SUPPL.
@article{f870035b3a4346c48ee1e53f51b6c841,
title = "Hepatocellular carcinoma: Systemic treatments",
abstract = "Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, with increasing incidence in Western countries. Many pharmacologic treatments have been tested against HCC; most of them belong to three categories: chemotherapy, hormone therapy, and immunotherapy. Neither single agent nor combination chemotherapy have demonstrated a clear reproducible advantage in terms of overall survival; therefore, systemic or intraarterial chemotherapy, should not be considered as standard strategies for patients with HCC. Tamoxifen and antiandrogen therapy were not effective in prolonging survival when tested in randomized, controlled trials. Promising results have been obtained with octreotide in a small randomized trial, but confirmation studies are needed. Although adoptive immunotherapy was effective in the adjuvant setting, interferon should be further investigated in this setting or investigated as a preventive strategy in cirrhotic patients. On the contrary, interferon does not seem to have a role in advanced disease, where it is tolerated poorly. In the future, innovative and promising therapeutic strategies will be tested in HCC, including new biologic target-based drugs, cyclooxygenase inhibitors, and gene therapy.",
keywords = "Chemotherapy, Hepatocellular carcinoma, Hormonal therapy, Interferon, Pharmacologic treatment",
author = "{Di Maio}, Massimo and {De Maio}, Ermelinda and Francesco Perrone and Sandro Pignata and Bruno Daniele",
year = "2002",
month = "11",
doi = "10.1097/00004836-200211002-00007",
language = "English",
volume = "35",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "5 SUPPL.",

}

TY - JOUR

T1 - Hepatocellular carcinoma

T2 - Systemic treatments

AU - Di Maio, Massimo

AU - De Maio, Ermelinda

AU - Perrone, Francesco

AU - Pignata, Sandro

AU - Daniele, Bruno

PY - 2002/11

Y1 - 2002/11

N2 - Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, with increasing incidence in Western countries. Many pharmacologic treatments have been tested against HCC; most of them belong to three categories: chemotherapy, hormone therapy, and immunotherapy. Neither single agent nor combination chemotherapy have demonstrated a clear reproducible advantage in terms of overall survival; therefore, systemic or intraarterial chemotherapy, should not be considered as standard strategies for patients with HCC. Tamoxifen and antiandrogen therapy were not effective in prolonging survival when tested in randomized, controlled trials. Promising results have been obtained with octreotide in a small randomized trial, but confirmation studies are needed. Although adoptive immunotherapy was effective in the adjuvant setting, interferon should be further investigated in this setting or investigated as a preventive strategy in cirrhotic patients. On the contrary, interferon does not seem to have a role in advanced disease, where it is tolerated poorly. In the future, innovative and promising therapeutic strategies will be tested in HCC, including new biologic target-based drugs, cyclooxygenase inhibitors, and gene therapy.

AB - Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, with increasing incidence in Western countries. Many pharmacologic treatments have been tested against HCC; most of them belong to three categories: chemotherapy, hormone therapy, and immunotherapy. Neither single agent nor combination chemotherapy have demonstrated a clear reproducible advantage in terms of overall survival; therefore, systemic or intraarterial chemotherapy, should not be considered as standard strategies for patients with HCC. Tamoxifen and antiandrogen therapy were not effective in prolonging survival when tested in randomized, controlled trials. Promising results have been obtained with octreotide in a small randomized trial, but confirmation studies are needed. Although adoptive immunotherapy was effective in the adjuvant setting, interferon should be further investigated in this setting or investigated as a preventive strategy in cirrhotic patients. On the contrary, interferon does not seem to have a role in advanced disease, where it is tolerated poorly. In the future, innovative and promising therapeutic strategies will be tested in HCC, including new biologic target-based drugs, cyclooxygenase inhibitors, and gene therapy.

KW - Chemotherapy

KW - Hepatocellular carcinoma

KW - Hormonal therapy

KW - Interferon

KW - Pharmacologic treatment

UR - http://www.scopus.com/inward/record.url?scp=0036841150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036841150&partnerID=8YFLogxK

U2 - 10.1097/00004836-200211002-00007

DO - 10.1097/00004836-200211002-00007

M3 - Article

C2 - 12394214

AN - SCOPUS:0036841150

VL - 35

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - 5 SUPPL.

ER -